Company / Return on Equity (ROE)
Taysha Gene Therapies, Inc. Return on Equity (ROE) History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-44.1%
FY2025
5-year range
-17493.6% / -44.1%
FY2021-FY2025
Trend
+70.4%
vs FY2024
Sector context
#124 of 190
Health Care
What the data says
Taysha Gene Therapies, Inc. reports negative total equity of -44.1% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-44.1% in FY2025 with a 5-year CAGR of -20.3%.
Improved from -17493.6% to -44.1% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +138.8pp
- 5-Year Change
- -20.3pp
- 10-Year Change
- -
Sector benchmark
#124 of 190 in Health CareTop 65% of 190This company -44.1% Sector average -50.3%
▼
+12.3% above sector average
Key checks
Key Insights
- In FY2025, return on equity (roe) increased 70.4% year-over-year.
- Currently 6.2pp above the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2020.
- Lowest return on equity (roe) in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -1.03 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -44.1% | +70.4% |
| FY2024 | -148.9% | +99.1% |
| FY2023 | -17493.6% | -9460.9% |
| FY2022 | -183.0% | +0.0% |
| FY2021 | -183.0% | -666.2% |
| FY2020 | -23.9% | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026